A397030 Stock Overview
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AprilBio Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,330.00 |
| 52 Week High | ₩25,900.00 |
| 52 Week Low | ₩12,460.00 |
| Beta | 0 |
| 1 Month Change | 1.43% |
| 3 Month Change | -13.55% |
| 1 Year Change | 25.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 49.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| A397030 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.4% | 2.9% | 2.7% |
| 1Y | 25.1% | 26.7% | -5.9% |
Return vs Industry: A397030 underperformed the KR Biotechs industry which returned 26.7% over the past year.
Return vs Market: A397030 exceeded the KR Market which returned -5.9% over the past year.
Price Volatility
| A397030 volatility | |
|---|---|
| A397030 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 13.0% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A397030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A397030's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Sang-Hoon Cha | www.aprilbio.com |
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops products based on its long-acting protein medicine platform technology. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases.
AprilBio Co.,Ltd. Fundamentals Summary
| A397030 fundamental statistics | |
|---|---|
| Market cap | ₩371.31b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A397030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A397030 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A397030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 13:40 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AprilBio Co.,Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eunji Kang | Korea Investment & Securities Co., Ltd. |
| Haejoo Wi | Korea Investment & Securities Co., Ltd. |